Fortress Biotech Q1 net loss narrows to $17.7M; FDA accepts DFD-29 NDA for rosacea

Fortress Biotech, Inc.

2025-Q1 EPS reported -$1.04 vs consensus -$0.50 ▼ miss (-106.0%)

Consolidated net revenue $13.0M, all from dermatology products, up 7% YoY driven by Qbrexza and Accutane.
Net loss attributable to common stockholders $(17.7)M ($1.03/share) vs $(23.5)M ($3.47/share) in Q1 2023.
Cash and equivalents $85.8M as of March 31, up from $83.4M; includes $11M January direct offering.
FDA accepted DFD-29 NDA with PDUFA date Nov 4, 2024; potential only oral therapy for rosacea lesions and erythema.
Triplex CMV vaccine Phase 2 for HIV/CMV fully enrolled; topline data Q4 2024; liver transplant trial dosed first patient.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Fortress Biotech, Inc. reported financial results for first quarter ended March 31, 2024.

Period: first quarter ended March 31, 2024
Result: reported results

Exact text from the filing

Fortress Biotech, Inc. issued a press release to provide a corporate update and to announce its financial results for the three months ended March 31, 2024.

View on SEC.gov

1436 earnings releases filed in the last 30 days. Browse all earnings releases →

Fortress Biotech, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-24-061958

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.